65 results about "Skin medications" patented technology

The present invention relates to a transdermal drug delivery system comprising a dermal drug delivery patch and a heating element compartment securable to the dermal drug delivery patch. A freely transferrable heating element is securable within the heating element compartment. A drug can be administered transdermally using the present invention by placing the dermal drug delivery patch upon a patient's skin at an administration site. A heating element compartment is secured to the dermal drug delivery patch and a freely transferrable heating element is placed within the heating element compartment. The heating element provides controlled heat to the dermal drug patch and the patient's skin aid thereby improves dermal drug administration.

Methods and apparatus for improving administration of drugs through the use of heat and other physical means. The present invention relates to the use of heat and other physical means in conjunction with specially designed dermal drug delivery systems, conventional commercial dermal drug delivery systems, or drugs delivered into a sub-skin depot site via injection and other methods to alter, mainly increase, the drug release rate from the dermal drug delivery systems or the depot sites to accommodate certain clinical needs.

The invention relates to a cosmetic or dermopharmaceutical composition, as well as these uses. The invention relates mainly to a cosmetic or dermopharmaceutical composition, notably an anti-wrinkle cosmetic or dermopharmaceutical composition, comprising an enzyme which is insoluble in an aqueous medium, in admixture with at least one cosmetically or dermopharmaceutically acceptable excipient. This composition is mainly used for limiting reactions of irritation and / or of allergy during topical use of this composition.

Cosmetic or dermopharmaceutical compositions containing Pseudoalteromonas ferment extract for the treatment and / or care of the skin, scalp and / or nails, preferably to improve the barrier function of the skin, scalp and / or nails, and specifically for the treatment and / or care of those conditions, disorders and / or pathologies of the skin, scalp and / or nails associated with an alteration in the keratinization process.

The invention relates to topical use of at least one UGT inducer for the preparation of a cosmetic or dermopharmaceutical composition comprising a dermatologically acceptable carrier to protect and / or enhance the state of the skin and prevent and / or treat imperfections of the skin.

Topical use of teprenone in a cosmetic or dermopharmaceutical composition as an active preventing and / or limiting the skin cells sénescence and / or protecting the general state of the skin.

The invention relates to novel cosmetic or dermopharmaceutical compositions for topical use which are used to prevent the symptoms of cutaneous slackening and, more specifically, to treat the visible signs of ageing and fatigue, such as bags and circles under the eyes. The inventive compositions comprise, in a cosmetically-acceptable medium, a combination of at least two, and preferably three, components selected from: a) hesperidin or the derivatives thereof; b) A.C.E. enzyme inhibitor dipeptides; and c) oligopeptides R2-(AA)n-Pro-Arg-OH, wherin (AA)n is a peptide chain, (AA) is any amino acid or any derivative of any amino acid, n is included between 1 and 3, and R2═H or an alkyl chain having a carbon length of between C2 and C22.

The invention discloses a skin model and application. The method comprises separately culturing epidermal cells and dermal cells derived from fetus scalp, newborn prepuce or adult scalp, and subculturing, wherein the used culture medium and culture method can maintain multiple functions of skin cells; separately digesting the cultured and proliferated multifunctional epidermal cells and dermal cells into single cells, and mixing to obtain suspension; transferring onto a semipermeable polymer or silica gel membrane substrate for incubation; transplanting cells on adhesive film to a receptor. The method can regenerate human intact functional skin and hair, the regenerated skin contains an epidermal layer, a dermal layer and a subcutaneous tissue as well as skin appendant organs. The skin model regenerated by the method disclosed by the invention can be used for study of human skin diseases, screening of skin drugs, and development of cell products for treating wound and other skin diseases.

Cosmetic or dermopharmaceutical compositions containing, in a dermatologically acceptable carrier, at least one diterpene among: cafestol, kahweol and chemical derivatives are useful for slimming treatments including prevent and / or treat cellulite or orange peel and / or to refine contours of the face, skin firming, to reduce the steatomery of the thighs, to decrease the volume / fatty overload of the spare tire at the hips, to reduce “love handles”, both on men and women.

A fully integrated, independently accurately performing, active transdermal medicament patch includes a flexible substrate with an adhesive-coated therapeutic face carrying a medicament reservoir. A circuit non-removably carried on the substrate and driven by a light-weight power source causes a substantially constant current to flow for a predetermined therapy period through the reservoir and the skin against which the therapeutic face is disposed. Net electrical polarity of the medicament determines the interconnection of circuit and power source to skin. The circuit includes a field effect transistor or an operational amplifier with a zener diode or a voltage regulator. A timer non-removably carried on the substrate disables the circuit following functioning the therapy period. An active transdermal medicament delivery system employs a single patch or pair of patches physically and electrically connected by a distensible tether.

The present invention is drawn toward systems, devices, and methods of dermal drug delivery. The system can comprise a gel-triggering agent and a drug-containing composition including a drug and a gelling agent, wherein the drug-containing composition forms a soft, coherent solid when contacted with the gel-triggering agent. A cavity patch is also included having an open cavity configured to be closed at least in part by a skin surface. The open cavity can be further configured to facilitate contact between the skin surface and the gel. The gel-triggering agent and the drug-containing composition can be positioned in the system such that they are kept isolated from one another until immediately before or during use.

The invention concerns novel molecules derived from noraporphine, as well as cosmetic and dermopharmaceutical compositions containing one or several of said derivatives, alone or combined with a plant extract, in particular glaucium flavum, and particularly preparations for reducing pigmentation, with anti-ageing effect or for slimming.

The invention relates to a novel tyramine derivate and a method for preparing the compound. The invention also relates to a cosmetic or medical skin composition having the compound, as well as the application of the compound in the skin care field, in particular to the application in order to release the over-pigmentation.

Cosmetic or dermopharmaceutical compositions which contain kombucha are disclosed. The present invention further relates to the use of kombucha and cosmetic or dermopharmaceutical compositions containing the same, alone or in combination, for the care of the skin, mucosae and skin appendages, and in particular for preventing the signs of endogenous and / or exogenous ageing.

Personal care products including cosmetics, grooming products and topical pharmaceutical products can be produced including a polypeptide of between 3 and 12 amino acids in length and a ceramide. These formulations are particularly useful in addressing wrinkles in human subjects and in particular facial skin and hands. Certain analogs and derivatives of these polypeptides may be used in these formulations and / or alone. Methods of using these formulations are also disclosed.

The invention relates to a process for the production of granules or powders, suitable as coating agents and binders for oral or dermal pharmaceutical forms, for cosmetics or food supplements, consisting essentially of (a) a copolymer, consisting of free radical-polymerized C1- to C4-esters of acrylic or methacrylic acid and further (meth)acrylate monomers which contain functional tertiary amino groups, (b) 3 to 25% by weight, based on (a), of an emulsifier having an HLB of at least 14, (c) 5 to 50% by weight, based on (a), of a C12- to C18-monocarboxylic acid or of a C12- to C18-hydroxyl compound, where the components (a), (b) and (c) are simultaneously or successively blended or mixed with one another, optionally with addition of a pharmaceutical active compound and / or further customary additives, fused in a heatable mixer, mixed, the melt is cooled and comminuted to give granules or powders.

The invention provides a compound clobetasol propionate liposome and a preparation thereof, which are mainly used for treating diseases such as psoriasis vulgaris, dermatitis, eczema and the like. The liposome prepared from neutral synthetic phospholipids, lipids with positive charges, and cholesterol can coat clobetasol propionate and vitamin A acid simultaneously, and is added with a cream substrate or gel substrate to be prepared into compound clobetasol propionate liposome cream or gel. Compared with the common cream, the liposome preparation has the advantages that: the amount of the medicine retained in skin is larger, the skin penetration rate is lower, the content of the medicine in local skin can be improved, the treatment index is improved, and transdermal absorption dose is reduced, so that the toxic and side effects of the medicine are reduced.

The present invention concerns a peptide of following formula I: R being a side chain having at least one heteroatom selected from sulfur, nitrogen and oxygen in a carbonyl form (C═O); R1 being either H or a lipophilic chain; R2 being either OH or a lipophilic chain. More particularly the present invention concerns a cosmetic composition comprising a peptide as recited above and a physiologically acceptable medium. Results on the activity of the compounds are obtained and on the general state of the skin and its appendages, in particular via the stimulation of extracellular matrix components.

Short sight, visual fatigue and ischemic ophthalmopathy belong to the cataract diseases of oculopathy and are mostly caused by emotion problems or body fluid loss, blood shortage, weak kidney and liver which lead to the disorder of entrails, no moistening of eyes, blood stasis, etc., thus causing the loss of sight and even other neopathy. The treatment principle is that the traditional Chinese medicine components which can strengthen the liver and the kidney, supplement blood and body fluid, activate blood circulation to dissipate blood stasis, invigorate the spleen, and be beneficial for moistening are selected; the medicinal materials are extracted (63 percent of effective components, 30 percent of film-forming agent and 7 percent of plasticizer) and blended evenly to make the Chinese medicinal plaster with the thickness of 0.08 to 0.12cm and the plaster is then dried at the normal temperature (the temperature is controlled below 40 DEG C), cut and packaged into a finished product. The medicine can be applied to the skin around the eye and be finally acted on the target area in the ocular fundus after being absorbed by capillary vessels of the skin into the blood circulation of the eye.

The invention relates to a process for the preparation of a coating and binding agent for oral or dermal pharmaceutical forms, essentially consisting of (a) a copolymer consisting of free-radical-polymerized C1 to C4 esters of acrylic or methacrylic acid and further (meth)acrylate monomers which contain functional tertiary ammonium groups, the coplymer being present in powdered form having an average particle size of 1–40 μm, (b) 3 to 15% by weight, based on (a), of an emulsifier having an HLB of at least 14 and (c) 5 to 50% by weight, based on (a), of a C12—to C18-monocarboxylic acid or a C12—to C18-hydroxyl compound, the components (a), (b) and (c) being blended or mixed with one another with or without addition of water and if appropriate with addition of a pharmaceutical active compound and further customary additives and the coating and binding agent being produced from the mixture by melting, casting, spreading or spraying. The invention further relates to the coating and binding agent itself.

The invention concerns novel molecules derived from noraporphine, as well as cosmetic and dermopharmaceutical compositions containing one or several of said derivatives, alone or combined with a plant extract, in particular glaucium flavum, and particularly preparations for reducing pigmentation, with anti-ageing effect or for slimming.

The present invention is drawn to systems and methods for treating warts. The system can comprise a wart treatment formulation comprising a substance for treating warts and a cavity patch (10) comprising an open cavity (18) being configured to become a closed cavity upon application and adherence to a skin surface (44). The closed cavity can be configured to contain the wart treatment formulation.

A method and formulation for the delivery of an active substance to the skin (epidermis, including the stratum corneum and viable epidermis, and dermis) of a subject. The formulation comprises oil-based or aqueous droplets comprising the active substance within a coating of nanoparticles, particularly silica nanoparticles. The active substance may be suitable for the treatment of a disease or condition which is localised, or at least partially localised, to the skin (eg skin cancer, psoriasis, eczema, infections including bacterial and fungal infections, acne, dermatitis, inflammation, and rheumatoid arthritis).

Extract of a bacterial strain for its use in treatment and / or care of the skin and / or mucous membranes, as well as its cosmetic and / or dermopharmaceutical compositions. In particular, its use for sebum reduction and skin firmness.

The invention discloses an ozagrel ester with the compounds of the ozagrel ester. The ozagrel ester is provided with a chemical structural formula as listed on the right. The compounds of the ozagrel ester comprise an ozagrel ester with the amount of effective treatment and a carrier accepted in medicine. The invention also discloses the preparation methods for the ozagrel ester and the compounds of the ozagrel ester. The ozagrel ester of the invention has good solubility and stability; besides, the compounds of ozagrel ester can be conveniently made into a plurality of liquid, solid, freeze-drying and mucosa or the skin medication agents.

The invention relates to a medicine composition which consists of active components and medicinal auxiliary materials and can directly act on skin. The medicine composition is characterized in that the active components comprise one of glucocorticoids and azulene sulfonate or one of salts of azulene sulfonate.

The invention belongs to the technical field of skin medicines, and particularly relates to acne-removing ointment and a preparation method thereof. The acne-removing ointment is prepared from the following components in percentage by weight: 5 to 20 percent of azelaic acid, 0.1 to 1 percent of menthol, 15 to 25 percent of fatty alcohol, 50 to 70 percent of polyhydric alcohol, 2 to 10 percent of emulsifier and 0.1 to 2 percent of polydimethylsiloxane. According to the acne-removing ointment disclosed by the invention, azelaic acid can exist in a formula in a dissolved state, and effective components can permeate into skin more easily, so that the treatment effect of acne is improved; meanwhile, the emulsifier and the fatty alcohol are added, so that azelaic acid dissolved by the polyhydricalcohol is slowly released, greasy feeling and adverse reaction caused by high-content polyhydric alcohol are relieved, and the low-temperature stability of the ointment is improved.

Ferment extract and exopolysaccharide of a bacterial strain for its use in treatment and / or care of the skin, as well as its cosmetic and / or dermopharmaceutical compositions. In particular, its use for skin aging, skin firmness and hydration.